-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20

Benzinga·05/12/2026 10:46:37
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.